Discontinue Metoprolol First
In this patient with severe symptomatic bradycardia (heart rate 30-40 bpm) and adequately controlled blood pressure (126/88 mmHg), metoprolol should be discontinued first. The profound bradycardia represents a life-threatening adverse effect that takes priority over blood pressure management, and the patient's BP is already at goal without needing all four agents.
Clinical Reasoning
Why Metoprolol Must Be Stopped
The patient's resting heart rate of 30-40 bpm is dangerously low and directly attributable to metoprolol. According to FDA labeling, bradycardia including sinus pause, heart block, and cardiac arrest have occurred with metoprolol use 1. The ACC/AHA heart failure guidelines explicitly state that if bradycardia is accompanied by dizziness or lightheadedness, physicians should decrease the dose of the beta-blocker 2, 3. At a heart rate this low, the patient is at risk for syncope, falls, and cardiac arrest.
Blood Pressure Status Supports Medication Reduction
With BP at 126/88 mmHg, the patient has achieved adequate control per 2017 ACC/AHA guidelines (goal <130/80 mmHg for most patients) 4, 5. Being on four antihypertensive agents with controlled BP indicates overtreatment, making this an appropriate time to deprescribe.
Why Not the Other Medications
Olmesartan (ARB): Should be maintained as a primary agent. The 2017 ACC/AHA guidelines classify ARBs as primary antihypertensive agents 4, 5, and they provide cardiovascular and renal protection without causing bradycardia.
Amlodipine (CCB): Also a primary agent per guidelines 4, 5. Importantly, the ACC/AHA guidelines specifically warn to avoid routine use of CCBs with beta-blockers because of increased risk of bradycardia and heart block 5, 6. This drug interaction is likely contributing to the severe bradycardia, making metoprolol removal even more critical.
Chlorthalidone (thiazide diuretic): Preferred as a primary agent with proven trial reduction of cardiovascular disease 4, 5. Chlorthalidone is specifically preferred over hydrochlorothiazide due to its prolonged half-life and superior outcomes data.
Beta-Blocker Considerations in Hypertension
The 2017 ACC/AHA guidelines clearly state that beta-blockers are not recommended as first-line agents unless the patient has ischemic heart disease or heart failure 4, 5, 6, 7. Without these specific indications mentioned in this case, metoprolol lacks a compelling indication beyond blood pressure control—which is already achieved with three other agents.
Safe Discontinuation Approach
Critical caveat: While metoprolol must be stopped due to severe bradycardia, the FDA warns against abrupt discontinuation, particularly if coronary artery disease is present 1. The label states: "When discontinuing chronically administered metoprolol, particularly in patients with coronary artery disease, the dosage should be gradually reduced over a period of 1 to 2 weeks."
Practical Algorithm:
If no history of coronary artery disease or recent acute coronary syndrome: Taper metoprolol over 1-2 weeks (e.g., reduce dose by 50% for one week, then discontinue)
If coronary artery disease is present or suspected: More gradual taper over 2 weeks with close monitoring, but do NOT delay discontinuation given the severe bradycardia
Monitor heart rate daily during taper and immediately after discontinuation
Reassess BP weekly during and after taper; if BP rises above goal, consider uptitrating remaining agents rather than restarting metoprolol
Common Pitfall to Avoid
Do not attempt to simply reduce the metoprolol dose while continuing it. At a heart rate of 30-40 bpm, even a reduced dose poses unacceptable risk. The goal is complete discontinuation, not dose adjustment.